Efficacy of Combination Therapy for Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study.
10.4111/kju.2006.47.5.536
- Author:
Kyo Ik MO
1
;
Kyung Seop LEE
;
Dae Gon KIM
Author Information
1. Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea. delommd@hanmail.net
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Pelvic pain;
Chronic disease;
Antibiotics;
Adrenergic alpha blockers
- MeSH:
Adrenergic alpha-Antagonists;
Anti-Bacterial Agents;
Chronic Disease;
Consensus;
Humans;
Levofloxacin;
Pelvic Pain*;
Prospective Studies*;
Prostatitis;
Quality of Life
- From:Korean Journal of Urology
2006;47(5):536-540
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The National Institute of Health (NIH) category III chronic nonbacterial prostatitis/chronic pelvic pain syndromes (CPPS) are commonly seen disorders; however, there has been no consensus on how to manage these patients. The purpose of this trial was to compare the efficacy of antibiotic monotherapy and antibiotic plus alpha-blocker combination therapy for the treatment of CPPS patients. MATERIALS AND METHODS: The study was comprised of 54 patients who were randomly placed into two groups: group I was treated with levofloxacin alone (28 patients), and group II was treated with levofloxacin and alfuzosin (26 patients). The levofloxacin, or the levofloxacin and alfuzosin were given to the respective groups for 8 weeks. The NIH Chronic Prostatitis Symptom Index (NIH-CPSI) was evaluated both before and after the treatment. RESULTS: Before the treatment, the mean CPSI of the group I patients was 23.1+/-8.1, and after the treatment, it was 15.6+/-5.6. For the group II, the mean CPSI before the treatment was 23.9+/-8.3, and after the treatment, it was 11.0+/-4.5. The difference between the pre-and post-treatment CPSI scores of group II was significantly larger than that of group I (p=0.001). The mean differences of the CPSI from the initial scores to the final scores in both groups were followed: 2.2 in group I and 4.3 in group II for the pain domain, 1.5 in group I and 2.8 in group II for the urinary domain, and 3.8 in group I and 5.7 in group II for the quality of life domain. CONCLUSIONS: Combination therapy of levofloxacin with alfuzosin appeared more effective for treating patients with chronic prostatitis/chronic pelvic pain syndrome than just administering antibiotic alone.
